Genetic diseases represent most of the people with rare diseases. The Orphanet portal for rare disease lists 5856 diseases in its database. Rare genetic diseases are less commonplace than other illnesses, but the modern-day treatment expenses of these diseases are very excessive which might also cause a higher impact on budgets for healthcare systems. Researchers, healthcare industries, mall and medium-sized businesses (SMEs), as well as fundamental pharmaceutical corporations, are paying greater attention to regenerative medicine treatments. the goods of gene therapies are designed now not most effective to deal with the signs and symptoms however the underlying causes as nicely. Aside from advancements in remedies, gene healing procedures assist in shortening recuperation time, lessen the chance of organ rejection, costs of remedies, and reduce the risks of detrimental reactions or contamination. Gene and cellular therapies are consequently nice over conventional treatment options.
The restrained and uneven findings on pricing, reimbursement, health economics, and market access get admission to on gene and cell treatments exhibited. On the other hand, there is a demand for adjusting the regulatory programs all around the world. Consequently, to recognize the possible position of gene and cell healing therapies' economic burden on health systems and to unravel the therapeutic ability of regenerative medication, each public and private investment are needed.
The research questions that we wish to address through this Research Topic includes:
What is the regulatory structure for gene and cell therapy in different countries?
How have the legislations impacted the economy of the regenerative healthcare industry of the case countries?
What does the current market of gene and cell therapies look like?
The future of market access of gene and cell therapies.
Topic Editor Dr. Güvenç Koçkaya is the CEO of ECONiX, a consultancy services for government and academic institutes, pharmaceuticals, medical devices and healthcare services companies. All other Topic Editors have no conflicts of interests to declare.
Genetic diseases represent most of the people with rare diseases. The Orphanet portal for rare disease lists 5856 diseases in its database. Rare genetic diseases are less commonplace than other illnesses, but the modern-day treatment expenses of these diseases are very excessive which might also cause a higher impact on budgets for healthcare systems. Researchers, healthcare industries, mall and medium-sized businesses (SMEs), as well as fundamental pharmaceutical corporations, are paying greater attention to regenerative medicine treatments. the goods of gene therapies are designed now not most effective to deal with the signs and symptoms however the underlying causes as nicely. Aside from advancements in remedies, gene healing procedures assist in shortening recuperation time, lessen the chance of organ rejection, costs of remedies, and reduce the risks of detrimental reactions or contamination. Gene and cellular therapies are consequently nice over conventional treatment options.
The restrained and uneven findings on pricing, reimbursement, health economics, and market access get admission to on gene and cell treatments exhibited. On the other hand, there is a demand for adjusting the regulatory programs all around the world. Consequently, to recognize the possible position of gene and cell healing therapies' economic burden on health systems and to unravel the therapeutic ability of regenerative medication, each public and private investment are needed.
The research questions that we wish to address through this Research Topic includes:
What is the regulatory structure for gene and cell therapy in different countries?
How have the legislations impacted the economy of the regenerative healthcare industry of the case countries?
What does the current market of gene and cell therapies look like?
The future of market access of gene and cell therapies.
Topic Editor Dr. Güvenç Koçkaya is the CEO of ECONiX, a consultancy services for government and academic institutes, pharmaceuticals, medical devices and healthcare services companies. All other Topic Editors have no conflicts of interests to declare.
